MK-8719

Skip to product information
1 of 1

Selleck Chemicals

SKU:S8890-5MG

Regular price €321,00 EUR
Regular price Sale price €321,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
Quantity
View full details

MK-8719 is an inhibitor linked to Autophagy and related pathway-oriented research. In practice, this places the compound in experiments that measure autophagic flux, lysosomal turnover, and stress adaptation in autophagy models.

The pathway annotation connects MK-8719 to Autophagy, supporting experiments that monitor autophagic flux, lysosomal turnover, and stress adaptation across biochemical, cellular, or phenotypic assay formats. This context is compatible with autophagy-flux, lysosome, and cargo-clearance assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In autophagy models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

  • Pathway perturbation studies connected to Autophagy
  • Concentration-response inhibition and target-dependence studies
  • Phenotypic profiling in autophagy models
  • Combination studies with orthogonal perturbagens

Overall, MK-8719 is well suited to pathway-oriented studies that need a defined compound input for Autophagy readouts in autophagy models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.

Pathways:
Autophagy
Research Area:
Autophagy
CAS No.:
1382799-40-7
Molecular Weight:
268.28
Formula:
C₉H₁₄F₂N₂O₃S
SMILES:
CCN=C1NC2C(C(C(OC2S1)C(F)F)O)O
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.